Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013
Author:
Affiliation:
1. Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation Research; US Food and Drug Administration; Silver Spring Maryland
2. Office of Minority Health; US Food and Drug Administration; Silver Spring Maryland
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference23 articles.
1. Surveillance, Epidemiology, End Results (SEER) Program National Cancer Institute. SEER*Stat fact sheets: prostate http://seer.cancer.gov/statfacts/html/prost.html 2013
2. Cancer statistics for African Americans, 2013;Desantis;CA Cancer J Clin,2013
3. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee;Newman;Cancer,2006
4. Cancer disparities research partnership in Lakota Country: clinical trials, patient services, and community education for the Oglala, Rosebud, and Cheyenne River Sioux tribes;Rogers;Am J Public Health,2005
5. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer;Shavers;Med Care,2004
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The National Cancer Institute’s Cancer Disparities Research Partnership Program: a unique funding model 20 years later;JNCI: Journal of the National Cancer Institute;2023-09-14
2. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer;BJUI Compass;2023-08-15
3. Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast;The Oncologist;2023-07-07
4. Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study;Cancer Medicine;2022-12-20
5. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting;Prostate Cancer and Prostatic Diseases;2022-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3